Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study

Methylglyoxal (MGO), a major precursor for advanced glycation end products, is increased in diabetes. In diabetic rodents, inhibition of MGO prevents cardiovascular disease (CVD). Whether plasma MGO levels are associated with incident CVD in people with type 1 diabetes is unknown. We included 159 individuals with persistent normoalbuminuria and 162 individuals with diabetic nephropathy (DN) from the outpatient clinic at Steno Diabetes Center. We measured MGO at baseline and recorded fatal and nonfatal CVD over a median follow-up of 12.3 years (interquartile range 7.6–12.5 years). Data were analyzed by Cox regression, with adjustment for sex, age, HbA1c, DN, diabetes duration, smoking, systolic blood pressure, antihypertensive medication, and BMI. During follow-up, 73 individuals suffered at least one CVD event (36 fatal and 53 nonfatal). Higher MGO levels were associated with total, fatal, and nonfatal incident CVD (hazard ratios [HRs] 1.47 [95% CI 1.13–1.91], 1.42 [1.01–1.99], and 1.46 [1.08–1.98], respectively). We observed a similar trend for total mortality (HR 1.24 [0.99–1.56]). This study shows for the first time in our knowledge that plasma MGO levels are associated with cardiovascular events in individuals with type 1 diabetes. MGO may explain, at least in part, the increased risk for CVD in type 1 diabetes.

[1]  T. Lauritzen,et al.  Methylglyoxal is associated with changes in kidney function among individuals with screen‐detected Type 2 diabetes mellitus , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[2]  H. Pijl,et al.  Energy restriction and Roux-en-Y gastric bypass reduce postprandial α-dicarbonyl stress in obese women with type 2 diabetes , 2016, Diabetologia.

[3]  Paul J Thornalley,et al.  Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation , 2016, Diabetes.

[4]  C. Schalkwijk.  Vascular AGE-ing by methylglyoxal: the past, the present and the future , 2015, Diabetologia.

[5]  C. Stehouwer,et al.  Post–Glucose Load Plasma α-Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study , 2015, Diabetes Care.

[6]  B. Vanderhyden,et al.  Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin‐treated, apolipoprotein E‐deficient mice , 2014, Physiological reports.

[7]  D. van der A,et al.  Plasma Advanced Glycation End Products Are Associated With Incident Cardiovascular Events in Individuals With Type 2 Diabetes: A Case-Cohort Study With a Median Follow-up of 10 Years (EPIC-NL) , 2014, Diabetes.

[8]  M. Huijberts,et al.  Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. , 2014, European heart journal.

[9]  H. Parving,et al.  The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1 , 2013, Diabetologia.

[10]  Alan W. Stitt,et al.  Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology , 2012, Diabetologia.

[11]  M. Cooper,et al.  Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice , 2011, Diabetologia.

[12]  H. Parving,et al.  Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes , 2011, Diabetes Care.

[13]  S. Ito,et al.  Methylglyoxal Is a Predictor in Type 2 Diabetic Patients of Intima-Media Thickening and Elevation of Blood Pressure , 2010, Hypertension.

[14]  C. Stehouwer,et al.  Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress , 2010, Diabetologia.

[15]  H. Hammes,et al.  Hyperglycemia Impairs Proteasome Function by Methylglyoxal , 2009, Diabetes.

[16]  R. Roeder,et al.  Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia , 2008, The Journal of experimental medicine.

[17]  H. Parving,et al.  Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. , 2005, Kidney international.

[18]  Merlin C. Thomas,et al.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.

[19]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[20]  H. Parving,et al.  Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin I–Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients , 1995, Diabetes.

[21]  M. Brownlee,et al.  Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.

[22]  J. Shaw,et al.  Glycemic control and excess mortality in type 1 diabetes. , 2015, The New England journal of medicine.

[23]  C. Schalkwijk,et al.  Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen , 2014, Clinical chemistry and laboratory medicine.

[24]  C. Stehouwer,et al.  Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes , 2013, Diabetologia.

[25]  M. Brownlee.  Insight Review Articles , 2022 .